Merve Yuce

Merve Yuce

Auto-generated profile, based on publicly available information

Merve Yuce

Department of Chemical Engineering Istanbul Technical University Istanbul Turkey

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2021 in Proteins: Structure, Function, and Bioinformatics
Verified
Journal Article
Open access
PDF file
MYMerve Yuce
Merve Yuce
ECErdem Cicek
Erdem Cicek
TITugce Inan
Tugce Inan
ADAslihan Basak Dag
Aslihan Basak Dag
OKOzge Kurkcuoglu
Ozge Kurkcuoglu
FSFethiye Aylin Sungur
Fethiye Aylin Sungur
The novel coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) still has serious negative effects on health, social life, and economics. Recently, vaccines from various companies have been urgently approved to control SARS‐CoV‐2 infections. However, any specific antiviral drug has not been confirmed so far for regular treatment. An important target is the main protease (Mpro), which plays a major role in replication of the virus. In this study, Gaussian and residue network models are employed to reveal two distinct potential allosteric sites on Mpro that can be evaluated as drug targets besides the active site. Then, Food and Drug Administration (FDA)‐approved drugs are docked to three distinct sites with flexible docking using AutoDock Vina to identify potential drug candidates. Fourteen best molecule hits for the active site of Mpro are determined. Six of these also exhibit high docking scores for the potential allosteric regions. Full‐atom molecular dynamics simulations with MM‐GBSA method indicate that compounds docked to active and potential allosteric sites form stable interactions with high binding free energy (∆Gbind) values. ∆Gbind values reach −52.06 kcal/mol for the active site, −51.08 kcal/mol for the potential allosteric site 1, and − 42.93 kcal/mol for the potential allosteric site 2. Energy decomposition calculations per residue elucidate key binding residues stabilizing the ligands that can further serve to design pharmacophores. This systematic and efficient computational analysis successfully determines ivermectine, diosmin, and selinexor currently subjected to clinical trials, and further proposes bromocriptine, elbasvir as Mpro inhibitor candidates to be evaluated against SARS‐CoV‐2 infections.

4 July 2024 in Journal of Molecular Graphics and Modelling
Verified
Journal Article
Closed access
MYMerve Yuce
Merve Yuce
BABeril Ates
Beril Ates
NYNesrin Isil Yasar
Nesrin Isil Yasar
FSFethiye Aylin Sungur
Fethiye Aylin Sungur
OKOzge Kurkcuoglu
Ozge Kurkcuoglu

14 April 2021
Verified
Preprint
Open access
PDF file
MYMerve Yuce
Merve Yuce
ECErdem Cicek
Erdem Cicek
TİTuğçe İnan
Tuğçe İnan
ADAslıhan Başak Dağ
Aslıhan Başak Dağ
ÖKÖzge Kürkçüoğlu
Özge Kürkçüoğlu
FSFethiye Aylin Sungur
Fethiye Aylin Sungur
The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still has serious negative effects on health, social life, and economics. Recently, vaccines from various companies have been urgently approved to control SARS-CoV-2 infections. However, any specific antiviral drug has not been confirmed so far for regular treatment. An important target is the main protease (Mpro), which plays a major role in replication of the virus. In this study, Gaussian and residue network models are employed to reveal two distinct potential allosteric sites on Mpro that can be evaluated as drug targets besides the active site. Then, FDA-approved drugs are docked to three distinct sites with flexible docking using AutoDock Vina to identify potential drug candidates. 14 best molecule hits for the active site of Mpro are determined. 6 of these also exhibit high docking scores for the potential allosteric regions. Full-atom molecular dynamics simulations with MM-GBSA method indicate that compounds docked to active and potential allosteric sites form stable interactions with high binding free energy (∆Gbind) values. ∆Gbind values reach -52.06 kcal/mol for the active site, -51.08 kcal/mol for the potential allosteric site 1, and -42.93 kcal/mol for the potential allosteric site 2. Energy decomposition calculations per residue elucidate key binding residues stabilizing the ligands that can further serve to design pharmacophores. This systematic and efficient computational analysis successfully determines ivermectine, diosmin and selinexor currently subjected to clinical trials, and further proposes bromocriptine, elbasvir as Mpro inhibitor candidates to be evaluated against SARS-CoV-2 infection

13 February 2026 in Proteins: Structure, Function, and Bioinformatics
Verified
Journal Article
Closed access
MYMerve Yuce
Merve Yuce
OKOzge Kurkcuoglu
Ozge Kurkcuoglu

7 April 2026 in RSC Advances
Verified
Journal Article
Open access
PDF file
MYMerve Yuce
Merve Yuce
EKEzgi Koman
Ezgi Koman
FSFethiye Aylin Sungur
Fethiye Aylin Sungur
AYAyten Yazgan-Karatas
Ayten Yazgan-Karatas
OKOzge Kurkcuoglu
Ozge Kurkcuoglu
A hierarchical VS pipeline to target the bacterial ribosome PTC and in vitro translation assays identified Mitoxantrone as a potent inhibitor of E. coli protein synthesis, and Plerixafor, Olcegepant, and Ziritaxestat as lead compounds.